Efavirenz as a potential drug for the treatment of triple-negative breast cancers

被引：0
|
作者：
P.-T. Chiou
S. Ohms
P. G. Board
J. E. Dahlstrom
D. Rangasamy
M. G. Casarotto
机构：
[1] The Australian National University,ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research
[2] The Australian National University,The John Curtin School of Medical Research
[3] The Australian National University,Anatomical Pathology, ACT Pathology, Canberra Hospital and ANU Medical School, ANU College of Health and Medicine
来源：
Clinical and Translational Oncology | 2021年 / 23卷
关键词：
Triple-negative breast cancer; Efavirenz; LINE-1; Retrotransposon; Fatty acid metabolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 363
页数：10
相关论文
共 50 条
  • [41] Novel Selenoesters as a Potential Tool in Triple-Negative Breast Cancer Treatment
    Radomska, Dominika
    Czarnomysy, Robert
    Szymanowska, Anna
    Radomski, Dominik
    Dominguez-Alvarez, Enrique
    Bielawska, Anna
    Bielawski, Krzysztof
    CANCERS, 2022, 14 (17)
  • [42] CDKs inhibitor: potential monotherapy for treatment of triple-negative breast cancer
    Rajput, Sandeep
    Guo, Zhanfang
    Ma, Cynthia
    CANCER RESEARCH, 2015, 75
  • [43] Potential role of targeted therapies in the treatment of triple-negative breast cancer
    Jia, Lee Yueh
    Shanmugam, Muthu K.
    Sethi, Gautam
    Bishayee, Anupam
    ANTI-CANCER DRUGS, 2016, 27 (03) : 147 - 155
  • [44] New potential target for the treatment of triple-negative breast cancer identified
    不详
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (01) : 11 - 11
  • [45] Molecular profiling of triple-negative endometrial cancers (TNEC) and triple-negative breast cancers (TNBC) to reveal unique expression profiles.
    Jones, Nathaniel L.
    Xiu, Joanne
    Reddy, Sandeep K.
    Wright, Jason Dennis
    Burke, William M.
    Tergas, Ana Isabel
    Hou, June YiJuan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [46] Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers
    Anantaraju, Hasitha Shilpa
    Battu, Madhu Babu
    Viswanadha, Srikant
    Sriram, Dharmarajan
    Yogeeswari, Perumal
    MOLECULAR DIVERSITY, 2016, 20 (02) : 521 - 535
  • [47] TIMP-4-prognostic marker and treatment target for triple-negative breast cancers
    Kunkel, Emily K.
    DuHadaway, James
    Sutanto-Ward, Erika
    Birnhak, Lauren N.
    Ringqvist, Jenny R.
    Ali, Zonera A.
    Gilman, Paul B.
    Prendergast, George C.
    Wallon, U. Margaretha
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [48] Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers
    Hasitha Shilpa Anantaraju
    Madhu Babu Battu
    Srikant Viswanadha
    Dharmarajan Sriram
    Perumal Yogeeswari
    Molecular Diversity, 2016, 20 : 521 - 535
  • [49] RNA nanoparticles for targeted therapies of triple-negative breast cancers
    Danai, Leyla
    Ge, Eva
    Afonin, Kirill A.
    MOLECULAR THERAPY NUCLEIC ACIDS, 2023, 33 : 885 - 886
  • [50] A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
    Qingwang Chen
    Yaqing Liu
    Yuechen Gao
    Ruolan Zhang
    Wanwan Hou
    Zehui Cao
    Yi-Zhou Jiang
    Yuanting Zheng
    Leming Shi
    Ding Ma
    Jingcheng Yang
    Zhi-Ming Shao
    Ying Yu
    Scientific Data, 9
12345